The objective response rate (all partial responses) was 12.2% in the sorafenib group and 0.5% in the placebo group
Answer: Tirzepatide is a once-weekly injectable medication that activates two gut hormone receptors, GLP-1 and GIP, to reduce appetite, slow stomach emptying, and support steady fat loss as part of a structured weight management plan
Yamuna Nagar, Haryana - 135003 Vendor Details Country of origin: India 834 MRP 1111.425% off Save more with additional offers Get up to 75 cashback on a minimum order value (MOV) of 499 and above, valid once per customer
Risk stratification integrates non-modifiable factors (advanced age, African American/Hispanic/South Asian ethnicity, TCF7L2 polymorphisms, autosomal dominant polycystic kidney disease) with modifiable determinants (pre-transplant dysglycemia, obesity, hypomagnesemia, hepatitis C and cytomegalovirus infections, acute rejection, and diuretic use)